Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 385 to 388 of 388 entries
Sorted by: Best Match Show Resources per page
Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials.

Respiratory medicine

Kirla KT, Nemes S, Betts J, Kristensson C, Mo J, Asimus S, Sadiq MW, Redlich E, Koernicke T, Fuhr R, Brailsford W, Keen C, Hagberg A, Mäenpää J.
PMID: 34879298
Respir Med. 2021 Dec 02;191:106705. doi: 10.1016/j.rmed.2021.106705. Epub 2021 Dec 02.

Diffusing capacity for carbon monoxide (DLCO) was measured in a phase I single ascending dose study after inhalation of AZD8154 or placebo in healthy participants at baseline (DLCO

Cite
Kirla KT, Nemes S, Betts J, et al. Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials. Respir Med. 2021;191:106705doi: 10.1016/j.rmed.2021.106705.
Kirla, K. T., Nemes, S., Betts, J., Kristensson, C., Mo, J., Asimus, S., Sadiq, M. W., Redlich, E., Koernicke, T., Fuhr, R., Brailsford, W., Keen, C., Hagberg, A., & Mäenpää, J. (2021). Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials. Respiratory medicine, 191106705. https://doi.org/10.1016/j.rmed.2021.106705
Kirla, Krishna Tulasi, et al. "Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials." Respiratory medicine vol. 191 (2021): 106705. doi: https://doi.org/10.1016/j.rmed.2021.106705
Kirla KT, Nemes S, Betts J, Kristensson C, Mo J, Asimus S, Sadiq MW, Redlich E, Koernicke T, Fuhr R, Brailsford W, Keen C, Hagberg A, Mäenpää J. Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials. Respir Med. 2021 Dec 02;191:106705. doi: 10.1016/j.rmed.2021.106705. Epub 2021 Dec 02. PMID: 34879298.
Copy Download .nbib Format: NLM
Corrigendum to 'Associations of maternal and paternal mental health problems with offspring anxiety at age 20 years: Findings from a population-based prospective cohort study [Psychiatry Research 298 (2021) 113781].

Psychiatry research

Ayano G, Betts K, Lin A, Tait R, Alati R.
PMID: 33836893
Psychiatry Res. 2021 May;299:113922. doi: 10.1016/j.psychres.2021.113922. Epub 2021 Apr 06.

No abstract available.

Cite
Ayano G, Betts K, Lin A, et al. Corrigendum to 'Associations of maternal and paternal mental health problems with offspring anxiety at age 20 years: Findings from a population-based prospective cohort study [Psychiatry Research 298 (2021) 113781]. Psychiatry Res. 2021;299:113922doi: 10.1016/j.psychres.2021.113922.
Ayano, G., Betts, K., Lin, A., Tait, R., & Alati, R. (2021). Corrigendum to 'Associations of maternal and paternal mental health problems with offspring anxiety at age 20 years: Findings from a population-based prospective cohort study [Psychiatry Research 298 (2021) 113781]. Psychiatry research, 299113922. https://doi.org/10.1016/j.psychres.2021.113922
Ayano, Getinet, et al. "Corrigendum to 'Associations of maternal and paternal mental health problems with offspring anxiety at age 20 years: Findings from a population-based prospective cohort study [Psychiatry Research 298 (2021) 113781]." Psychiatry research vol. 299 (2021): 113922. doi: https://doi.org/10.1016/j.psychres.2021.113922
Ayano G, Betts K, Lin A, Tait R, Alati R. Corrigendum to 'Associations of maternal and paternal mental health problems with offspring anxiety at age 20 years: Findings from a population-based prospective cohort study [Psychiatry Research 298 (2021) 113781]. Psychiatry Res. 2021 May;299:113922. doi: 10.1016/j.psychres.2021.113922. Epub 2021 Apr 06. PMID: 33836893.
Copy Download .nbib Format: NLM
DNA methylation signatures associated with cardiometabolic risk factors in children from India and The Gambia: results from the EMPHASIS study.

Clinical epigenetics

Antoun E, Issarapu P, di Gravio C, Shrestha S, Betts M, Saffari A, Sahariah SA, Sankareswaran A, Arumalla M, Prentice AM, Fall CHD, Silver MJ, Chandak GR, Lillycrop KA.
PMID: 35000590
Clin Epigenetics. 2022 Jan 09;14(1):6. doi: 10.1186/s13148-021-01213-3.

BACKGROUND: The prevalence of cardiometabolic disease (CMD) is rising globally, with environmentally induced epigenetic changes suggested to play a role. Few studies have investigated epigenetic associations with CMD risk factors in children from low- and middle-income countries. We sought...

Cite
Antoun E, Issarapu P, di Gravio C, et al. DNA methylation signatures associated with cardiometabolic risk factors in children from India and The Gambia: results from the EMPHASIS study. Clin Epigenetics. 2022;14(1):6doi: 10.1186/s13148-021-01213-3.
Antoun, E., Issarapu, P., di Gravio, C., Shrestha, S., Betts, M., Saffari, A., Sahariah, S. A., Sankareswaran, A., Arumalla, M., Prentice, A. M., Fall, C. H. D., Silver, M. J., Chandak, G. R., Lillycrop, K. A. (2022). DNA methylation signatures associated with cardiometabolic risk factors in children from India and The Gambia: results from the EMPHASIS study. Clinical epigenetics, 14(1), 6. https://doi.org/10.1186/s13148-021-01213-3
Antoun, Elie, et al. "DNA methylation signatures associated with cardiometabolic risk factors in children from India and The Gambia: results from the EMPHASIS study." Clinical epigenetics vol. 14,1 (2022): 6. doi: https://doi.org/10.1186/s13148-021-01213-3
Antoun E, Issarapu P, di Gravio C, Shrestha S, Betts M, Saffari A, Sahariah SA, Sankareswaran A, Arumalla M, Prentice AM, Fall CHD, Silver MJ, Chandak GR, Lillycrop KA. DNA methylation signatures associated with cardiometabolic risk factors in children from India and The Gambia: results from the EMPHASIS study. Clin Epigenetics. 2022 Jan 09;14(1):6. doi: 10.1186/s13148-021-01213-3. PMID: 35000590.
Copy Download .nbib Format: NLM
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH.
PMID: 34112709
Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10.

PURPOSE: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood.PATIENTS AND METHODS: Here, we...

Cite
Byrne KT, Betts CB, Mick R, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27(16):4574-4586doi: 10.1158/1078-0432.CCR-21-1047.
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., Alanio, C., Ferreira, A. P., Park, B. S., Ohtani, T., Huffman, A. P., Väyrynen, S. A., Dias Costa, A., Kaiser, J. C., Lacroix, A. M., Redlinger, C., Stern, M., Nowak, J. A., Wherry, E. J., Cheever, M. A., Wolpin, B. M., Furth, E. E., Jaffee, E. M., Coussens, L. M., & Vonderheide, R. H. (2021). Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4574-4586. https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne, Katelyn T, et al. "Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4574-4586. doi: https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. PMID: 34112709; PMCID: PMC8667686.
Copy Download .nbib Format: NLM
Showing 385 to 388 of 388 entries